Kiwi, I agree, AMRN has exclusivity here too but you know how that works out if generics get to enter for Marine market. We also see how GL is being used in spite of being ineffective and not bio similar to Vascepa. If KD gets FAP indication, which I doubt they will succeed, it will be another pharmaceutical EPA available in EU and pricing will dictate which drug gets written and filled at the pharmacy. I admit that I don’t know how EU treats off label scripts and exclusivity in a situation like this, if it should arise.
News 
Market Data 
Discover 
